Change represents evolving board capabilities as Tetra enters next stage of its corporate development
OTTAWA, ON / ACCESSWIRE / June 22, 2020 / Tetra Bio-Pharma Inc. (“Tetra” or the “Company”) (TSXV:TBP)(OTCQB:TBPMF), a bio-pharmaceutical company engaged in cannabinoid-derived drug discovery and development, today announces the departure of one of its members of the Board of Directors (the “Board).
The Tetra Board has received notification that Mr. Gregory Drohan has resigned from the Board effective immediately. The Board would like to thank Mr. Drohan who was previously the President of Church and Dwight Canada, for his contributions to Tetra over the past 2.5 years. He has helped to shape Tetra from a start-up company to an operating Biotechnology company with a rich pipeline of patent protected products. Dr. Bill Cheliak, Chairman of the Board said that, “Greg brought his many years of corporate experience in consumer and OTC medicinal products to help Tetra build a solid foundation to help us stage our next phase of development and growth. It has been my pleasure to work closely with Greg as a valuable member of the Board. He has played a significant role guiding the company through its formative years.”
“On behalf of the Board, we’d like to thank Greg for his important contributions to Tetra. His vast corporate experience and leadership skills contributed significantly to building the vision and mission of Tetra Bio-Pharma,” said Dr. Guy Chamberland, Chief Executive Officer, Chief Regulatory Officer and Board member. “Looking ahead, Dr. Cheliak and I are preparing Tetra for the next stage of value. Our portfolio of innovative products is unique and represents the solid foundation for a biopharmaceutical company.”
The Board has undertaken a process to expand the number of directors on the Board in order to better position the Board to lead the Company in its next growth phase. As a first step, the Board intends to appoint 2 additional directors with relevant expertise in the biotechnology industry. The Board has already identified suitable candidates and hopes to announce appointments in the coming weeks.
About Tetra Bio-Pharma
Tetra Bio-Pharma (TSXV:TBP)(OTCQB:TBPMF) is a biopharmaceutical leader in cannabinoid-based drug discovery and development with a Health Canada approved, and FDA reviewed and approved, clinical program aimed at bringing novel prescription drugs and treatments to patients and their healthcare providers. The Company has several subsidiaries engaged in the development of an advanced and growing pipeline of Bio Pharmaceuticals, Natural Health and Veterinary Products containing cannabis and other medicinal plant-based elements. With patients at the core of what we do, Tetra Bio-Pharma is focused on providing rigorous scientific validation and safety data required for inclusion into the existing bio pharma industry by regulators, physicians and insurance companies.
For more information visit: www.tetrabiopharma.com.
Source: Tetra Bio-Pharma
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, the success of the Company’s research and development strategies, including the success of this product or any other product, the applicability of the discoveries made therein, the successful and timely completion and uncertainties related to the regulatory process, the timing of clinical trials, the timing and outcomes of regulatory or intellectual property decisions and other risks disclosed in the Company’s public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.
For further information, please contact Tetra Bio-Pharma Inc.:
Alpha Bronze, LLC
Mr. Pascal Nigen
Phone: + 1 (646) 255-0433
Ms. Carol Levine APR, FCPRS
Phone: + 1 (416) 425-9143 ext. 226
Mobile: + 1 (514) 703-0256
SOURCE: Tetra Bio-Pharma
View source version on accesswire.com: